Impact of Baseline IgE levels on Exacerbations and Asthma Symptom Control After Omalizumab Initiation

Methods Patients >=12 y/o identified as omalizumab candidates by their treating physicians and with access to treatment through insurance or other funding were enrolled in PROSPERO (n=801); US-based, multicenter, prospective, 48-week observational study of patients with allergic asthma initiating...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of allergy and clinical immunology 2018-02, Vol.141 (2), p.AB195-AB195
Hauptverfasser:	Casale, Thomas B., Gonzalez-Reyes, Erika G., Yang, Ming, Trzaskoma, Benjamin L., Griffin, Noelle M., Chipps, Bradley E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Asthma Immunoglobulin E Immunotherapy Monoclonal antibodies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!